|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/09/17 Zafgen, Inc. S-3 6:1.4M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-3 Registration Statement for Securities Offered HTML 242K
Pursuant to a Transaction
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 443K
3: EX-4.4 Instrument Defining the Rights of Security Holders HTML 476K
4: EX-5.1 Opinion re: Legality HTML 14K
5: EX-12.1 Statement re: Computation of Ratios HTML 12K
6: EX-23.1 Consent of Experts or Counsel HTML 5K
| EX-12.1 |
Exhibit 12.1
| Years ended December 31, | Six months ended June 30, |
|||||||||||||||
| 2016 | 2015 | 2014 | 2017 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Loss from continuing operations |
$ | (58,225 | ) | $ | (73,813 | ) | $ | (35,532 | ) | $ | (26,801 | ) | ||||
| Add back: fixed charges |
676 | 913 | 925 | 184 | ||||||||||||
| Total loss from continuing operations |
(57,549 | ) | (72,900 | ) | (34,607 | ) | (26,617 | ) | ||||||||
| Fixed charges: |
||||||||||||||||
| Interest expense |
381 | 575 | 680 | 92 | ||||||||||||
| Noncash interest and other |
295 | 338 | 245 | 92 | ||||||||||||
| Total fixed charges |
676 | 913 | 925 | 184 | ||||||||||||
| Ratio of earnings to fixed charges |
* | * | * | * | ||||||||||||
| Deficiency of earnings available to cover fixed charges (1) |
$ | (58,225 | ) | $ | (73,813 | ) | $ | (35,532 | ) | $ | (26,801 | ) | ||||
| * | Less than one to one coverage. |
| (1) | Losses in each period. Insufficient earnings to cover fixed charges by the amounts indicated. |
| This ‘S-3’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/9/17 | 10-Q | ||
| 6/30/16 | 10-Q, 4, 8-K, DEF 14A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/17 SEC UPLOAD¶ 11/01/17 1:128K Larimar Therapeutics, Inc. |